Compare Sanofi SA (SNY) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Sanofi SA trades at $40.02 (market cap $95.18B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.61 (market cap $330.98M). The key difference: Sanofi SA is far larger — about 287.6× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Sanofi SA pays a 6.01% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| SNY | XDTE | |
|---|---|---|
Market Cap | $95.18B | $330.98M |
Volume | 2,995,646 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $44.76 |
52-Week Low | $39.51 | $36.00 |
Typical Hold Time | 94 Days | 54 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
